ELMSFORD, N.Y., June 10, 2015 /PRNewswire/
-- BioScrip®, Inc. (NASDAQ: BIOS) ("BioScrip"),
today announced the extension of the expiration date of its offer
(the "Exchange Offer") to exchange up to $200,000,000 in aggregate principal amount
of 8.875% Senior Notes due 2021 (the "Exchange Notes"), which have
been registered under the Securities Act of 1933, as amended (the
"Securities Act"), for an equal aggregate principal amount of its
outstanding 8.875% Senior Notes due 2021 (the "Old Notes") that
were originally issued on February 11, 2014, in a transaction
exempt from registration under the Securities Act. The terms and
conditions of the Exchange Offer are set forth in the Prospectus
dated May 7, 2015 (the "Prospectus")
and the related Letter of Transmittal (the "Letter of
Transmittal").
The Exchange Offer, previously set to expire at 5:00 p.m., New York
City time, on June 9, 2015,
will now expire at 5:00 p.m.,
New York City time, on
June 16, 2015, unless further
extended or earlier terminated.
Except for the extension described above, all other terms and
conditions of the Exchange Offer remain unchanged. The extension of
the Exchange Offer has been made to allow all qualifying holders of
outstanding Old Notes who have not yet tendered their Old Notes for
exchange to do so. As of 5:00 p.m.,
New York City time, on
June 9, 2015, approximately
$199,725,000 in aggregate principal
amount, or approximately 99.8625%, of the Old Notes had been
validly tendered for exchange and not withdrawn.
This press release is neither an offer to purchase, nor a
solicitation for acceptance of an offer to sell, any
securities. The Company is making the Exchange Offer only by,
and pursuant to the terms of, the Prospectus and the related Letter
of Transmittal. The complete terms and conditions of the
Exchange Offer are set forth in the Prospectus and the Letter of
Transmittal. Holders are urged to read these documents
carefully.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion
and home care management solutions. BioScrip partners
with physicians, hospital systems, skilled nursing facilities,
healthcare payors, and pharmaceutical manufacturers to provide
patients access to post-acute care
services. BioScrip operates with a commitment to bring
customer-focused pharmacy and related healthcare infusion therapy
services into the home or alternate-site setting. By collaborating
with the full spectrum of healthcare professionals and the
patient, BioScrip provides cost-effective care that is
driven by clinical excellence, customer service, and values that
promote positive outcomes and an enhanced quality of life for those
it serves. BioScrip provides its infusion services from
over 70 locations across 28 states.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bioscrip-announces-extension-of-expiration-date-of-exchange-offer-for-its-8875-senior-notes-due-2021-300096946.html
SOURCE BioScrip, Inc.